University of Kansas Medical Center

• Between 40 to 80 years of age - Physician diagnosed chronic obstructive pulmonary disease (COPD) ≥1 year - Post-bronchodilator forced expiratory volume in 1 second (post-BD FEV1) ≥ 20% and ≤ 70% of predicted value and FEV1/FVC (forced expiratory volume in 1 second /forced vital capacity) <0.70 - Former or current smokers ≥10 pack-years - Chronic Airways Assessment Test (CAAT) ≥10 - ≥2 moderate or ≥1 severe COPD exacerbations in the prior year - Triple (ICS+LABA+LAMA) COPD therapy ≥12 consecutive weeks - EOS (blood eosinophil count) ≥ 150 cells/μL - 18.0 ≤ Body Mass Index ≤ 40.0 kg/m2

Participants are excluded from the study if any of the following criteria apply: - Asthma, including pediatric asthma, or ACOS - Sgnificant pulmonary disease other than COPD - Long-term oxygen therapy >4.0 L/min or requirement of >2.0 L/minO2 saturation to maintain oxygen saturation >88% - Unstable disorder that can impact participants safety or study outcomes - Active or incompletely treated tuberculosis - Current or past malignancies - Concomitant therapies: - long-term macrolides or iPDE-4 unless on stable therapy for >6 months - any biologic therapy or systemic immunosuppressant within 8 weeks or 5 half-lives prior to Screening The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial